78P - Examination of prognostic factors in cases receiving UFT as postoperative adjuvant chemotherapy for lung cancer

Date 17 April 2015
Event ELCC 2015
Session Poster lunch
Topics Anti-Cancer Agents & Biologic Therapy
Non-Small-Cell Lung Cancer, Early Stage
Translational Research
Presenter Kimitoshi Nawa
Citation Annals of Oncology (2015) 26 (suppl_1): 18-23. 10.1093/annonc/mdv048
Authors K. Nawa, R. Yoneyama, M. Kakihana, N. Kajiwara, T. Ohira, N. Ikeda
  • Thoracic Surgery, Tokyo Medical University Hospital, 160-0023 - Tokyo/JP



Although the 2012 version of the clinical practice guidelines for lung cancer published by the Japan Lung Cancer Society recommends performing a tegafur-uracil (UFT) compound drug therapy on cases of non-small cell lung cancer for stage 1A and 1B tumors measuring >2 cm in diameter after surgery, we often encounter cases of recurrence and death.


Among 2,724 cases of total surgical removal of non-small cell lung cancer performed between January 1997 and December 2007, we examined 168 cases with stage 1B T2a tumors treated with UFT to clarify the prognostic factors in these cases. We examined age, sex, tumor diameter, vascular invasion, lymphatic involvement, pleural invasion, histologic degree of differentiation, tissue, and CEA.


The age range was 38 to 85 years (median 66 years), and there were 108 men and 60 women. The 5-year overall survival rate was 80.3%. Death occurred in 49 cases (29.2%). On univariate analysis, men (p = 0.001), more than tumor diameter 4cm (p = 0.022) vascular invasion (p = 0.001), and non-adenocarcinoma (p = 0.011) were identified as significant prognostic factors. On multivariate analysis, male sex (p = 0.003), and more than tumor diameter 4cm (p = 0.048) were found to be significant prognostic factors.


It was inferred that men and tumor diameter are a primary prognostic factors in cases receiving UFT as postoperative adjuvant chemotherapy. We need to consider a more careful follow-up during UFT administration as postoperative adjuvant chemotherapy in stage 1B T2a tumors.


All authors have declared no conflicts of interest.